secwatch.observer — SEC 8-K summary
======================================

Issuer:     LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK:        0001062822
Form:       8-K
Filed at:   2024-10-16T23:59:59+00:00
Accession:  0001062822-24-000054
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexicon licenses sotagliflozin ex-US/Europe to Viatris for $25M upfront plus milestones
--------------------------------------------------------------------------------

- Exclusive license to Viatris for sotagliflozin development and commercialization outside US and Europe.
- Viatris pays $25M upfront; Lexicon eligible for up to $12M regulatory and $185M sales milestones.
- Tiered royalties: low double-digit to upper-teens percentages of net sales in licensed territory.
- Lexicon to supply drug under a separate manufacturing and supply agreement with Viatris.
- Viatris responsible for regulatory approvals, commercialization, and any additional clinical trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1062822/000106282224000054/0001062822-24-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1062822/000106282224000054/lxrx-20241016.htm
  HTML page:      https://secwatch.observer/filing/0001062822-24-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer